id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-003565-14g33n7j	Frey, Sharon E	Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly	2019-03-01		.txt	text/plain	4145	188	48	We evaluated the immunogenicity and safety of an MF59adjuvanted, cell culture-derived, H5N1 subunit influenza virus vaccine in 2 phase II studies; vaccine was administered as either a full-or half-dose formulation to healthy adult or elderly subjects. In conclusion, two 7.5-μg doses of a cell culture-derived, MF59-adjuvanted H5N1 vaccine administered 3 weeks apart were well tolerated and highly immunogenic, raised no safety concerns, and induced robust antibody responses in adult and elderly subjects that met all the immunogenicity criteria required for pandemic vaccine licensure by both the US and European regulatory authorities. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects	./cache/cord-003565-14g33n7j.txt	./txt/cord-003565-14g33n7j.txt